Skip to Primary Navigation

Skip to main content

Bill to limit US biotech companies doing business with China advances

Chinese flag flying above shipyard.
Photo: Cheng Xin/Getty Images

Kevin Kinsella

2 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The new bill would have government agencies referring to the Department of Defense’s 1260H list of Chinese military companies operating in the US.

The US Senate and the House of Representatives have released the final text of the 2026 National Defense Authorization Act.

Included within the text is the updated Biosecure Act, which would restrict how US pharmaceutical and biotechnology companies do business with Chinese companies that work with the Chinese military. 

, , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience